Health Care · Orthopedic, Prosthetic & Surgical Appliances & Supplies

SMTI Sanara MedTech Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 714256118 filings
Russell 2000

SMTI at a glance

Sanara MedTech Inc. (SMTI, SEC CIK 714256) filed its latest 10-K annual report on March 24, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as September 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Sanara MedTech Inc. (SMTI) reported revenue of $103.1 million (up 19.0% from FY2024) and a net loss of $37.6 million. Diluted EPS was -$4.36.
  • As of September 30, 2026, 20 institutional investment managers tracked by SignalX reported holding Sanara MedTech Inc. (SMTI) shares worth $40.4 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$103.1M
+19.0% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
20 funds
$40.4M · +2 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly added merger risk: FTC Second Request received October 15, 2026, extending HSR waiting period until 30 days after substantial compliance
  • Regulatory risk: FTC may withhold authorization or impose conditions, restrictions, or costs that delay or prevent completion
  • Financial risk: Failed merger could trigger a $9,660,336 termination fee payable to MiMedx
  • Operational risk: Merger uncertainty may increase employee attrition and hiring costs
  • Legal risk: Shareholder litigation could impose defense costs or obtain an injunction blocking the merger

Management Discussion & Analysis

  • Revenue $28.4M, up 8% YoY from $26.3M, driven by soft tissue repair sales up 10% to $25.7M
  • Gross margin approximately 93% vs 93% YoY, with bone fusion sales down 5% to $2.8M
  • Net loss from continuing operations $1.3M vs $0.8M net income, Adjusted EBITDA $5.6M vs $4.9M
  • Cash $16.8M vs $16.6M at December 31, 2025, operating cash flow $3.5M versus $2.8M YoY
  • Outlook: cash expected to fund operations, merger costs and capital expenditures for at least 12 months; FTC Second Request extends merger review

AI summary of the SMTI 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release announces Sanara MedTech’s financial results for the quarter ended September 30, 2026
  • Exhibit 99.1 contains the detailed quarterly results and management commentary for investor review

Item EX-99.1: Item EX-99.1

  • Q3 revenue $28.4M, up 8%, led by soft tissue repair sales up 10% to $25.7M
  • Gross margin held at 93%, while operating income fell to $0.7M from $2.9M amid $3.0M merger-related costs
Filed Oct 29, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • THP assets sold October 6, 2026 to an unrelated third party for approximately $2 million
  • Divestiture includes business software products and related intellectual property
Filed Oct 16, 2026Full analysis →

Item 8.01: Other Events

  • FTC issued a Second Request on October 15, 2026, extending HSR review of MiMedx’s proposed acquisition
  • Merger waiting period now runs until 30 days after substantial compliance, unless extended or terminated earlier

AI summaries of SMTI 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for SMTI

Don't miss the next SMTI filing

  • Alerts as it files. A push when SMTI files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut SMTI, by share count.
  • Ask anything. An AI agent that reads every SMTI filing and answers with sources.

SMTI alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Yon Seth DFSep 15, 2026$35.11
TANZBERGER ERIC DAJun 4, 2026-
Salamone Ann BealAJun 4, 2026-
Myers Keith GAJun 4, 2026-
DeSutter Robert AndrewAJun 4, 2026-
Nixon Ronald TAJun 4, 2026-
Mack Roszell IIIAJun 4, 2026-
Ortwein Sara NAJun 4, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$86.7M$103.1M
Gross Profit-$78.5M$95.6M
Operating Income--$6.7M$7.3M
Net Income--$9.7M-$37.6M
Gross Margin-90.6%92.7%
Op. Margin--7.7%7.1%
Net Margin--11.2%-36.4%
Balance Sheet
Total Assets$73.9M$88.1M$72.9M
Equity-$39.4M$5.9M
ROE--24.5%-632.5%
Per Share
EPS-$-1.14$-4.36
Cash Flow
Operating CF--$24K$6.8M
CapEx$265K$206K$4.6M

Source: XBRL data in Sanara MedTech Inc. (SMTI)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate SMTI share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
SMTI shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202620$40.4M
Q2 202618$22.5M
Q1 202616$12.1M
Q4 202515$14.5M
Q3 202517$21.4M
Q2 202517$19.0M
Q1 202514$13.4M
Q4 202412$14.1M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 129 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

SMTI filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 12, 2026Analysis
8-KNov 12, 2026Analysis-
8-KOct 29, 2026Analysis-
8-KOct 16, 2026Analysis-
8-KOct 1, 2026Analysis-
4Sep 16, 2026--
8-KAug 11, 2026Analysis-
10-QAug 11, 2026Analysis
8-KAug 11, 2026Analysis-
8-KJul 29, 2026Analysis-
8-KJun 9, 2026Analysis
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
8-KJun 4, 2026Analysis
4May 18, 2026-
10-QMay 12, 2026Analysis
8-KMay 11, 2026Analysis
4May 5, 2026--
4Apr 16, 2026--

Related Health Care companies

All Health Care →

SMTI SEC filings: frequently asked questions

Which institutions hold SMTI stock?

As of September 30, 2026, the largest Sanara MedTech Inc. (SMTI) holders among the 13F filers tracked by SignalX were BlackRock ($15.1 million), Vanguard Capital Management LLC ($6.8 million), Renaissance Technologies LLC ($4.0 million), State Street Corp ($2.4 million), Morgan Stanley ($1.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was SMTI's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Sanara MedTech Inc. (SMTI) reported revenue of $103.1 million (up 19.0% from FY2024) and a net loss of $37.6 million. Diluted EPS was -$4.36. The figures come from the XBRL data in the 10-K.

What did SMTI report in its latest 8-K?

Sanara MedTech Inc. (SMTI) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release announces Sanara MedTech’s financial results for the quarter ended September 30, 2026.

What are the latest SMTI SEC filings?

Sanara MedTech Inc. (SMTI) filed its latest 10-K annual report on March 24, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on September 16, 2026.

What is SMTI's SEC CIK number?

Sanara MedTech Inc. (SMTI)'s SEC Central Index Key (CIK) is 714256. EDGAR lists every SMTI filing under that number.

Ask anything about SMTI

The research agent reads SMTI's filings, financials, insider trades and 13F holders, then answers with sources.